340 related articles for article (PubMed ID: 32063029)
1. Adding new experimental arms to randomised clinical trials: Impact on error rates.
Choodari-Oskooei B; Bratton DJ; Gannon MR; Meade AM; Sydes MR; Parmar MK
Clin Trials; 2020 Jun; 17(3):273-284. PubMed ID: 32063029
[TBL] [Abstract][Full Text] [Related]
2. Assessing the impact of efficacy stopping rules on the error rates under the multi-arm multi-stage framework.
Blenkinsop A; Parmar MK; Choodari-Oskooei B
Clin Trials; 2019 Apr; 16(2):132-141. PubMed ID: 30648428
[TBL] [Abstract][Full Text] [Related]
3. Multi-arm multi-stage (MAMS) randomised selection designs: impact of treatment selection rules on the operating characteristics.
Choodari-Oskooei B; Blenkinsop A; Handley K; Pinkney T; Parmar MKB
BMC Med Res Methodol; 2024 Jun; 24(1):124. PubMed ID: 38831421
[TBL] [Abstract][Full Text] [Related]
4. Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes.
Bratton DJ; Parmar MK; Phillips PP; Choodari-Oskooei B
Trials; 2016 Jul; 17(1):309. PubMed ID: 27369182
[TBL] [Abstract][Full Text] [Related]
5. Treatment selection in multi-arm multi-stage designs: With application to a postpartum haemorrhage trial.
Choodari-Oskooei B; Thwin SS; Blenkinsop A; Widmer M; Althabe F; Parmar MK
Clin Trials; 2023 Feb; 20(1):71-80. PubMed ID: 36647713
[TBL] [Abstract][Full Text] [Related]
6. Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial.
Sydes MR; Parmar MK; Mason MD; Clarke NW; Amos C; Anderson J; de Bono J; Dearnaley DP; Dwyer J; Green C; Jovic G; Ritchie AW; Russell JM; Sanders K; Thalmann G; James ND
Trials; 2012 Sep; 13():168. PubMed ID: 22978443
[TBL] [Abstract][Full Text] [Related]
7. Designs for adding a treatment arm to an ongoing clinical trial.
Bennett M; Mander AP
Trials; 2020 Mar; 21(1):251. PubMed ID: 32143729
[TBL] [Abstract][Full Text] [Related]
8. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis.
Bratton DJ; Phillips PP; Parmar MK
BMC Med Res Methodol; 2013 Nov; 13():139. PubMed ID: 24229079
[TBL] [Abstract][Full Text] [Related]
9. Changing platforms without stopping the train: experiences of data management and data management systems when adapting platform protocols by adding and closing comparisons.
Hague D; Townsend S; Masters L; Rauchenberger M; Van Looy N; Diaz-Montana C; Gannon M; James N; Maughan T; Parmar MKB; Brown L; Sydes MR;
Trials; 2019 May; 20(1):294. PubMed ID: 31138292
[TBL] [Abstract][Full Text] [Related]
10. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
Sydes MR; Parmar MK; James ND; Clarke NW; Dearnaley DP; Mason MD; Morgan RC; Sanders K; Royston P
Trials; 2009 Jun; 10():39. PubMed ID: 19519885
[TBL] [Abstract][Full Text] [Related]
11. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.
Ventz S; Cellamare M; Parmigiani G; Trippa L
Biostatistics; 2018 Apr; 19(2):199-215. PubMed ID: 29036330
[TBL] [Abstract][Full Text] [Related]
12. Comparison of multi-arm multi-stage design and adaptive randomization in platform clinical trials.
Lin J; Bunn V
Contemp Clin Trials; 2017 Mar; 54():48-59. PubMed ID: 28089763
[TBL] [Abstract][Full Text] [Related]
13. Factorial versus multi-arm multi-stage designs for clinical trials with multiple treatments.
Jaki T; Vasileiou D
Stat Med; 2017 Feb; 36(4):563-580. PubMed ID: 27804166
[TBL] [Abstract][Full Text] [Related]
14. Statistical considerations of phase 3 umbrella trials allowing adding one treatment arm mid-trial.
Ren Y; Li X; Chen C
Contemp Clin Trials; 2021 Oct; 109():106538. PubMed ID: 34384890
[TBL] [Abstract][Full Text] [Related]
15. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit.
Royston P; Barthel FM; Parmar MK; Choodari-Oskooei B; Isham V
Trials; 2011 Mar; 12():81. PubMed ID: 21418571
[TBL] [Abstract][Full Text] [Related]
16. Multi-arm multi-stage clinical trials for time-to-event outcomes.
Dixit V; Mitra P; Simonsen K
J Biopharm Stat; 2021 Nov; 31(6):838-851. PubMed ID: 34606418
[TBL] [Abstract][Full Text] [Related]
17. Some recommendations for multi-arm multi-stage trials.
Wason J; Magirr D; Law M; Jaki T
Stat Methods Med Res; 2016 Apr; 25(2):716-27. PubMed ID: 23242385
[TBL] [Abstract][Full Text] [Related]
18. Adding experimental treatment arms to multi-arm multi-stage platform trials in progress.
Burnett T; König F; Jaki T
Stat Med; 2024 Jun; ():. PubMed ID: 38852991
[TBL] [Abstract][Full Text] [Related]
19. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials.
Tang H; Foster NR; Grothey A; Ansell SM; Goldberg RM; Sargent DJ
J Clin Oncol; 2010 Apr; 28(11):1936-41. PubMed ID: 20212253
[TBL] [Abstract][Full Text] [Related]
20. Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial.
Elm JJ; Palesch YY; Koch GG; Hinson V; Ravina B; Zhao W
J Biopharm Stat; 2012; 22(4):758-72. PubMed ID: 22651113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
